IL289474A - Substituted thiazolo-pyridine compounds as malt1 inhibitors - Google Patents

Substituted thiazolo-pyridine compounds as malt1 inhibitors

Info

Publication number
IL289474A
IL289474A IL289474A IL28947421A IL289474A IL 289474 A IL289474 A IL 289474A IL 289474 A IL289474 A IL 289474A IL 28947421 A IL28947421 A IL 28947421A IL 289474 A IL289474 A IL 289474A
Authority
IL
Israel
Prior art keywords
pyridine compounds
substituted thiazolo
malt1 inhibitors
malt1
inhibitors
Prior art date
Application number
IL289474A
Other languages
Hebrew (he)
Inventor
Gagan Kukreja
Nageswara Rao Irlapati
Arun Rangnath Jagdale
Gokul Keruji Deshmukh
Vinod Popatrao Vyavahare
Kiran Chandrashekhar Kulkarni
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Gagan Kukreja
Nageswara Rao Irlapati
Arun Rangnath Jagdale
Gokul Keruji Deshmukh
Vinod Popatrao Vyavahare
Kiran Chandrashekhar Kulkarni
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd, Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P Palle, Rajender Kumar Kamboj filed Critical Lupin Ltd
Publication of IL289474A publication Critical patent/IL289474A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL289474A 2016-07-29 2021-12-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors IL289474A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621026107 2016-07-29
PCT/IB2017/054612 WO2018020474A1 (en) 2016-07-29 2017-07-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors

Publications (1)

Publication Number Publication Date
IL289474A true IL289474A (en) 2022-02-01

Family

ID=59745317

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289474A IL289474A (en) 2016-07-29 2021-12-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors

Country Status (15)

Country Link
US (1) US20190275012A9 (en)
JP (1) JP2019522035A (en)
KR (1) KR20190033607A (en)
CN (1) CN110312724A (en)
AU (1) AU2017302182B2 (en)
CA (1) CA3032334A1 (en)
CL (1) CL2019000221A1 (en)
DO (1) DOP2019000020A (en)
IL (1) IL289474A (en)
MX (1) MX2019001132A (en)
PE (1) PE20190656A1 (en)
PH (1) PH12019500214A1 (en)
RU (1) RU2019104890A (en)
SG (1) SG11201900745VA (en)
WO (1) WO2018020474A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (en) 2016-12-21 2023-03-11 比利時商健生藥品公司 Pyrazole derivatives as malt1 inhibitors
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
WO2019099307A1 (en) * 2017-11-17 2019-05-23 Hepagene Therapeutics, Inc. Urea derivatives as inhibitors of ask1
CN111770759A (en) 2017-12-28 2020-10-13 通用医疗公司 Targeting the CBM semaphore complex induces regulatory T cells to inflame the tumor microenvironment
CN112585128B (en) * 2018-06-18 2023-02-21 詹森药业有限公司 Pyrazole derivatives as MALT1 inhibitors
MX2020013699A (en) * 2018-06-18 2021-05-12 Janssen Pharmaceutica Nv Pyrazole derivatives as malt1 inhibitors.
CN109265453A (en) * 2018-10-23 2019-01-25 华侨大学 It is a kind of as the semicarbazones analog derivative of caspase-3 activator and its application
KR102359143B1 (en) 2018-11-28 2022-02-08 다케다 야쿠힌 고교 가부시키가이샤 heterocyclic compounds
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
WO2021000855A1 (en) * 2019-07-01 2021-01-07 Qilu Regor Therapeutics Inc. Malt1 inhibitors and uses thereof
WO2021063735A1 (en) * 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
MX2022007171A (en) * 2019-12-27 2022-08-22 Schroedinger Inc CYCLIC COMPOUNDS AND METHODS OF USE OF THESE.
US20230192685A1 (en) 2020-05-27 2023-06-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
CA3198715A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
US20230414629A1 (en) * 2020-11-12 2023-12-28 Monopteros Therapeutics, Inc. Materials and methods of treating cancer
AU2022425324A1 (en) 2021-12-30 2024-05-30 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Tricyclic derivative inhibitor, preparation method therefor, and application thereof
CN116535424B (en) * 2022-01-26 2025-04-11 武汉誉祥医药科技有限公司 Tricyclic compounds as MALT1 inhibitors and pharmaceutical compositions and uses thereof
JPWO2023149450A1 (en) 2022-02-02 2023-08-10
EP4472734A1 (en) 2022-02-03 2024-12-11 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors
US20250326738A1 (en) * 2022-03-31 2025-10-23 Rarefied Biosciences, Inc. MALT1 Modulators and Uses Thereof
TW202345806A (en) 2022-03-31 2023-12-01 美商艾伯維有限公司 Thiazolo[5,4-b]pyridine malt-1 inhibitors
EP4628482A1 (en) * 2022-11-28 2025-10-08 Unimatec Co., Ltd. Fluorine-containing pyridone compound and method for producing same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
PL355148A1 (en) * 1999-11-05 2004-04-05 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
AU2003222667A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2008146259A2 (en) 2007-06-01 2008-12-04 University Of Lausanne Malt1 specific cleavage in assay and screening method
US8309523B2 (en) 2007-11-21 2012-11-13 Vib Vzw Inhibitors of MALT1 proteolytic activity and uses thereof
MX2014000963A (en) * 2011-07-26 2014-03-27 Gruenenthal Gmbh Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands.
EP3473254B1 (en) 2011-08-02 2024-01-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Phenothiazine derivatives for the treatment of autoimmune diseases
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
EP2916656B1 (en) 2012-11-09 2017-10-25 Cornell University Small molecule inhibitors of malt1
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
EP3013818B1 (en) 2013-06-26 2021-12-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for treating cancer
WO2015110406A1 (en) 2014-01-21 2015-07-30 Helmholtz Zentrum München Means and methods for detecting activated malt1
KR20170007311A (en) * 2014-05-28 2017-01-18 노파르티스 아게 Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
DE102015210224A1 (en) 2015-06-02 2016-12-08 Universitätsklinikum Hamburg-Eppendorf NEW ACTIVE FOR THE TREATMENT OF CANCER
JP6989505B2 (en) 2015-08-28 2022-01-05 コーネル ユニヴァーシティー MALT1 inhibitor and its use
JPWO2017057695A1 (en) 2015-09-30 2018-07-19 東レ株式会社 Diphenylpyrazole derivatives and their pharmaceutical use
MX2018005390A (en) 2015-11-13 2018-08-16 Novartis Ag Novel pyrazolo pyrimidine derivatives.
WO2018165385A1 (en) * 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof

Also Published As

Publication number Publication date
AU2017302182B2 (en) 2021-11-04
US20190275012A9 (en) 2019-09-12
DOP2019000020A (en) 2019-04-30
RU2019104890A (en) 2020-08-31
CL2019000221A1 (en) 2019-06-07
AU2017302182A1 (en) 2019-03-07
US20190160045A1 (en) 2019-05-30
JP2019522035A (en) 2019-08-08
SG11201900745VA (en) 2019-02-27
PH12019500214A1 (en) 2019-10-28
RU2019104890A3 (en) 2020-08-31
CN110312724A (en) 2019-10-08
PE20190656A1 (en) 2019-05-08
CA3032334A1 (en) 2018-02-01
WO2018020474A1 (en) 2018-02-01
KR20190033607A (en) 2019-03-29
MX2019001132A (en) 2019-12-16

Similar Documents

Publication Publication Date Title
IL289474A (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
HUS2400003I1 (en) Compounds useful as kinase inhibitors
HUE064473T2 (en) 4-azaindole compounds
PT3371190T (en) Heterocyclic compounds as pi3k-gamma inhibitors
ZA201700115B (en) Aminopyridazinone compounds as protein kinase inhibitors
IL255750A (en) Heterocyclic compounds as kinase inhibitors
ZA201804688B (en) New substituted cyanoindoline derivatives as nik inhibitors
IL266745B (en) Benzodiazolium compounds as enac inhibitors
GB201513481D0 (en) Inhibitor compounds
GB201403536D0 (en) Inhibitor compounds
GB201505658D0 (en) Inhibitor compounds
IL257202B (en) Compounds useful for inhibiting ror-gamma-t
IL264465B (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
HK40008964A (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors
GB201621619D0 (en) Inhibitor compounds
GB201522453D0 (en) Inhibitor compounds
GB201500644D0 (en) Inhibitor compounds
GB201520189D0 (en) Compound for use